# 20 Amelotex gel d / external. apply. 1% tube 30g
Category
Bruises, sprains
Scope of the drug
Musculoskeletal system
Release form
Gel
Manufacturer country
Russia
Way of introduction
On the skin
Release form, composition and packaging
Gel for external use is transparent or almost transparent, yellow or yellow with a greenish tinge, with a specific odor.
100 g
meloxicam (in terms of 100% substance) 1 g
methylpyrrolidone - 15 g, ethanol 95% - 25 g, carbomer - 0.9 g, trometamol - from 2 g to 3 g (up to pH 7.5-8.9), orange blossom oil - 0.015 g, lavender oil - 0.01 g, purified water - up to 100 g
30 g - aluminum tubes (1) - cardboard packs.
50 g - aluminum tubes (1) - cardboard packs.
pharmachologic effect
Has analgesic, anti-inflammatory effect.
The anti-inflammatory effect is associated with inhibition of the enzymatic activity of COX-2, which is involved in the biosynthesis of prostaglandins in the area of inflammation.
To a lesser extent, meloxicam acts on COX-1, which is involved in the synthesis of prostaglandin, which protects the gastrointestinal mucosa and takes part in the regulation of blood flow in the kidneys.
Meloxicam is a chondroneutral drug that does not adversely affect cartilage tissue, does not affect proteoglycan synthesis by articular cartilage chondrocytes.
When applied topically, the drug reduces or eliminates pain in the area of application of the gel, incl.
joint pain at rest and on movement.
Promotes increased range of motion.
Pharmacokinetics
In experimental studies on rabbits, it was found that when applied to the skin in the form of a gel, meloxicam is characterized by prolonged transdermal absorption, prolonged circulation in the blood and gradual elimination, significantly differing in kinetic characteristics from the i / m route of drug administration.
There is no evidence of significant absorption of meloxicam into the systemic circulation.
In the systemic circulation, meloxicam strongly binds to blood plasma proteins, mainly albumin (99%).
Undergoes metabolism in the liver with the formation of inactive metabolites.
It is excreted mainly in the form of metabolites in the urine and feces in approximately equal proportions.
Indications for use
- symptomatic therapy of osteoarthritis, accompanied by pain.
It is used for symptomatic therapy, reducing pain and inflammation
does not affect the progression of the disease.
Contraindications for use
- complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid or other NSAIDs (including history)
- violation of the integrity of the skin in the places of the intended application
- children and adolescents up to 18 years of age (efficacy and safety have not been established)
- pregnancy
- hypersensitivity to meloxicam and other components of the drug (including other NSAIDs).
The drug should be used with caution in case of gastric ulcer and duodenal ulcer (in the acute phase)
active gastrointestinal bleeding
progressive kidney disease
severe liver failure or active liver disease
confirmed hyperkalemia
inflammatory bowel disease
violation of coagulation
chronic heart failure
in elderly patients.
Dosage regimen
Outwardly.
Do not use internally.
A strip of gel about 4 cm long (2 g) is applied 2 times / day with a thin layer on clean, dry skin over the lesion and rubbed lightly for 2-3 minutes.
The duration of the course of therapy is determined individually, it can vary depending on the site of the lesion and the observed therapeutic effect and is no more than 4 weeks.
Overdose
Due to the low systemic absorption when applying Amelotex gel, an overdose with external use is unlikely.
Side effect
For drugs from the NSAID group for external use, the following side effects are described.
On the part of the skin: hyperemia, papular-vesicular rash, peeling, photosensitivity.
Allergic
Name ENG
AMELOTEX
Clinical and pharmacological group
NSAIDs for external use
ATX code
Non-steroidal anti-inflammatory drugs for external use
Dosage
1 g
Structure
meloxicam - 1 g.
Excipients: methylpyrrolidone - 15 g, ethanol 95% - 25 g, carbomer - 0.9 g, trometamol - from 2 g to 3 g (up to pH 7.5-8.9), orange blossom oil - 0.015 g, lavender oil - 0.01 g, water peeled - up to 100 g.
Indications
Symptomatic therapy of osteoarthritis, accompanied by pain.
It is used for symptomatic therapy, reducing pain and inflammation
does not affect the progression of the disease
Contraindications
Hypersensitivity to meloxicam and other components of the drug (including other NSAIDs)
complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid or other NSAIDs (including in history), violation of the integrity of the skin in the places of intended application
children's age (up to 18 years) (effectiveness and safety have not been established)
pregnancy.,
With care
peptic ulcer and 12 duodenal ulcer (in the acute phase), active gastrointestinal bleeding
progressive kidney disease, severe liver failure or active liver disease, confirmed hyperkalemia, inflammatory bowel disease, old age, coagulation disorders, chronic heart failure.
Storage conditions and periods
The drug should be stored out of reach of children at a temperature not exceeding 25C.
Do not freeze.
Shelf life is 2 years.
INN / Active ingredient
meloxicam
Specifications
Category
Bruises, sprains
Scope of the drug
Musculoskeletal system
Release form
Gel
Manufacturer country
Russia
Way of introduction
On the skin
Vacation conditions
Without recipe
Brand name
Sotex
The amount of the dosage form in the primary package
30 g
Primary packaging type
Tuba
Type of consumer packaging
Pack of cardboard
Dosage form
Gel for external use
Dosage (volume) of the substance in the preparation
meloxicam (in terms of 100% substance) 1 g
Drug action
Pain reliever
,
Anti-inflammatory
Expiration date in days
24
Package weight, g
45
Mode of application
:
Outwardly.
Do not use inside. < br> < br> A strip of gel about 4 cm long (2 g) is applied 2 times / day with a thin layer on clean, dry skin over the lesion and rubbed lightly for 2-3 minutes. < br> < br> The duration of the course of therapy is determined individually, it can vary depending on the site of the lesion and the observed therapeutic effect and is no more than 4 weeks.
Pharmaco-therapeutic group
:
Non-steroidal anti-inflammatory drug for external use
Anatomical and therapeutic characteristics
:
M02AA Topical non-steroidal anti-inflammatory drugs
Information on technical characteristics, delivery set, country of manufacture